Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Authors: Chen CT; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan., Chuang CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Source: Journal of hepatocellular carcinoma [J Hepatocell Carcinoma] 2025 Oct 15; Vol. 12, pp. 2341-2349. Date of Electronic Publication: 2025 Oct 15 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Dove Press Country of Publication: New Zealand NLM ID: 101674775 Publication Model: eCollection Cited Medium: Print ISSN: 2253-5969 (Print) Linking ISSN: 22535969 NLM ISO Abbreviation: J Hepatocell Carcinoma Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2253-5969
DOI:10.2147/JHC.S548785